2. Academic Validation
  3. De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder

De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder

  • Hum Genet. 2018 May;137(5):375-388. doi: 10.1007/s00439-018-1887-y.
Lot Snijders Blok 1 2 3,  Susan M Hiatt 4,  Kevin M Bowling 4,  Jeremy W Prokop 4,  Krysta L Engel 4,  J Nicholas Cochran 4,  E Martina Bebin 5,  Emilia K Bijlsma 6,  Claudia A L Ruivenkamp 6,  Paulien Terhal 7,  Marleen E H Simon 7,  Rosemarie Smith 8,  Jane A Hurst 9,  DDD study,  Heather McLaughlin 10,  Richard Person 10,  Amy Crunk 10,  Michael F Wangler 11,  Haley Streff 11,  Joseph D Symonds 12,  Sameer M Zuberi 12,  Katherine S Elliott 13,  Victoria R Sanders 14,  Abigail Masunga 15,  Robert J Hopkin 15 16,  Holly A Dubbs 17,  Xilma R Ortiz-Gonzalez 17,  Rolph Pfundt 1,  Han G Brunner 1 3 18,  Simon E Fisher 2 3,  Tjitske Kleefstra 19 20,  Gregory M Cooper 21
Affiliations

Affiliations

  • 1 Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
  • 2 Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands.
  • 3 Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
  • 4 HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.
  • 5 University of Alabama at Birmingham, Birmingham, AL, USA.
  • 6 Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • 7 Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • 8 Division of Genetics, Department of Pediatrics, Maine Medical Center, Portland, ME, USA.
  • 9 Great Ormond Street Hospital for Children, London, UK.
  • 10 GeneDx, 207 Perry Parkway, Gaithersburg, MD, 20877, USA.
  • 11 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • 12 Paediatric Neurosciences Research Group, University of Glasgow and Royal Hospital for Children, Glasgow, G51 4TF, UK.
  • 13 Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • 14 Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
  • 15 Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • 16 Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • 17 Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • 18 Department of Clinical Genetics, GROW School for Oncology and Developmental Biology, Maastricht UMC, Maastricht, The Netherlands.
  • 19 Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. [email protected].
  • 20 Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. [email protected].
  • 21 HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA. [email protected].
PMID: 29740699 DOI: 10.1007/s00439-018-1887-y
Abstract

Many genetic causes of developmental delay and/or intellectual disability (DD/ID) are extremely rare, and robust discovery of these requires both large-scale DNA sequencing and data sharing. Here we describe a GeneMatcher collaboration which led to a cohort of 13 affected individuals harboring protein-altering variants, 11 of which are de novo, in MED13; the only inherited variant was transmitted to an affected child from an affected mother. All patients had intellectual disability and/or developmental delays, including speech delays or disorders. Other features that were reported in two or more patients include autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, mild congenital heart abnormalities, and dysmorphisms. Six affected individuals had mutations that are predicted to truncate the MED13 protein, six had missense mutations, and one had an in-frame-deletion of one amino acid. Out of the seven non-truncating mutations, six clustered in two specific locations of the MED13 protein: an N-terminal and C-terminal region. The four N-terminal clustering mutations affect two adjacent Amino acids that are known to be involved in MED13 ubiquitination and degradation, p.Thr326 and p.Pro327. MED13 is a component of the CDK8-kinase module that can reversibly bind Mediator, a multi-protein complex that is required for Polymerase II transcription initiation. Mutations in several other genes encoding subunits of Mediator have been previously shown to associate with DD/ID, including MED13L, a paralog of MED13. Thus, our findings add MED13 to the group of CDK8-kinase module-associated disease genes.

Figures